INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
11/01/2019
Back to search
Official data from USPTO
KIOMEDINE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
KIOMEDINE
ST13
US500000079040678Class
1, 5, 42
Filing
79040678
Registration
3564818
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
11/01/2019
Classification
Registered
Trademark type
Word
Nice classes
1, 5, 42
Filing date
04/26/2007
Registration date
01/20/2009
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/25/2019
Last transaction
01/25/2019
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
HERSTAL, BE
Examiner
OKEKE, BENJAMIN
Law office
M30
Holders and representatives
Holders
K. P. (pessoa física)
KITOZYME s.a.
Representatives
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Plant biopolymers, namely, chitin, chitosans, chitin-glucan and derivatives of these products, for industrial and scientific applications
Class 5
Pharmaceutical and veterinary preparations made from biopolymers, used with other compounds to treat bleeding, wound, tissue disorders, inflammative disorders, immune disorders, degenerative disorders, cancer, neurological disorders, eye disorders, infections, as cell culture media, as excipients for systems involving the controlled release of actives, and used as a biomaterial component of medical devices for the treatment of wounds and burns, used in wound management, haemostatic systems, surgical systems, ophthafmologic devices, tissue engineering devices, cartilage substitutes, bone substitutes, skin reconstruction devices, periodontal products, vascular systems, and used in drug delivery systems in nanoparticles, microspheres, solutions, hydrogels, used in oral delivery, local delivery, mucosal delivery, nasal delivery, ocular delivery, transdermal delivery, intratumoral delivery
Class 42
[ Scientific and technological consulting and research services in the medical field, for the development of the formulation of medical devices and pharmaceutical systems ]
Publications
History of USPTO decisions and trademark events.
46 publications found
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
09/28/2019
INPC
INVALIDATION PROCESSED
09/28/2019
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
09/25/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/07/2019
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
01/25/2019
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
01/25/2019
ES71
TEAS SECTION 71 RECEIVED
01/18/2019
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
01/20/2018
RNWL
INTERNATIONAL REGISTRATION RENEWED
06/08/2017
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
05/19/2016
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
02/06/2015
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
02/06/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/06/2015
ES75
TEAS SECTION 71 & 15 RECEIVED
01/20/2015
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/04/2014
CHLD
CHANGE OF OWNER RECEIVED FROM IB
11/27/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/28/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/05/2013
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/15/2011
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/04/2009
FIMP
FINAL DISPOSITION PROCESSED
05/04/2009
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/20/2009
R.PR
REGISTERED-PRINCIPAL REGISTER
01/20/2009
PUBO
PUBLISHED FOR OPPOSITION
11/04/2008
NPUB
NOTICE OF PUBLICATION
10/15/2008
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/30/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/29/2008
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/26/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/26/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/26/2008
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/26/2008
CNFR
FINAL REFUSAL MAILED
03/31/2008
CNFR
FINAL REFUSAL WRITTEN
03/28/2008
ACEC
AMENDMENT FROM APPLICANT ENTERED
03/20/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/20/2008
ALIE
ASSIGNED TO LIE
03/19/2008
PAPER RECEIVED
03/03/2008
RFNT
REFUSAL PROCESSED BY IB
09/20/2007
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/31/2007
RFRR
REFUSAL PROCESSED BY MPU
08/31/2007
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/31/2007
CNRT
NON-FINAL ACTION WRITTEN
08/30/2007
DOCK
ASSIGNED TO EXAMINER
08/17/2007
NWAP
NEW APPLICATION ENTERED
08/17/2007
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/16/2007
Continuous trademark protection
Get notified about every new filing that threatens KIOMEDINE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.